Please try another search
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Name | Age | Since | Title |
---|---|---|---|
Geoffrey McCaughan | - | 2015 | Member of Hepatology Clinical Advisory Board |
Peter Damian Francis | 65 | 2006 | Independent Non-Executive Director |
George Dickson | - | - | Member of Scientific & Clinical Advisory Board |
Harry Janssen | - | 2015 | Member of Hepatology Clinical Advisory Board |
Keyur Patel | - | 2015 | Member of Hepatology Clinical Advisory Board |
Megan Joan Boston | 49 | 2016 | Executive Director |
J. Kevin Buchi | 66 | 2013 | Independent Non-Executive Director |
Jerel A. Banks | 47 | 2016 | Executive Chairman & CEO |
Edward F. Smith | 51 | 2020 | Independent Non-Executive Director |
Kishan Mehta | 38 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review